Abstract: This invention provides methods for treating endothelial dysfunction by administering an effective amount of citrulline to a patient. The patients may be suffering from acute respiratory distress syndrome (ARDS), sepsis, or infection by COVID-19 (Coronavirus Disease 2019); COVID-19 patients may be at risk of developing endothelial dysfunction, or they may be experiencing endothelial dysfunction. The effective amount of citrulline is sufficient to reduce the uncoupling of endothelial nitric oxide synthase (eNOS) or to reduce the formation of free radicals. Citrulline may be administered orally; intravenously; or both orally and intravenously in a sequential manner. Sequential administration of citrulline may be in three phases, such as (a) an initial phase in which citrulline is administered orally, (b) an intermediate phase wherein citrulline is administered intravenously, and (c) a final phase wherein citrulline is administered orally.

Abstract: A computing platform is provided to perform continuous monitoring of new genomic variants from external genomic databases and compare the new variants to genomic sequencing results for patients stored in long term cloud storage. The platform provides alerts to clinicians if a patient's genomic sequencing results match one or more of the new genomic variants.

Abstract: This invention provides methods for treating endothelial dysfunction by administering an effective amount of citrulline to a patient. The patients may be suffering from acute respiratory distress syndrome (ARDS), sepsis, or infection by COVID-19 (Coronavirus Disease 2019); COVID-19 patients may be at risk of developing endothelial dysfunction, or they may be experiencing endothelial dysfunction. The effective amount of citrulline is sufficient to reduce the uncoupling of endothelial nitric oxide synthase (eNOS) or to reduce the formation of free radicals. Citrulline may be administered orally; intravenously; or both orally and intravenously in a sequential manner. Sequential administration of citrulline may be in three phases, such as (a) an initial phase in which citrulline is administered orally, (b) an intermediate phase wherein citrulline is administered intravenously, and (c) a final phase wherein citrulline is administered orally.

Abstract: This invention is directed to citrulline therapy, where citrulline is administered to achieve a newly recognized therapeutic window. The results of a completed clinical trial has elucidated a therapeutic window for L-citrulline. Detailed analysis of clinical outcome as a function of the dose actually received reveals that patients falling within the dosing window showed significant improved effect compared to patients receiving a dose either below or above the dosing window. Patients benefiting from this invention are patients in need of supplemental citrulline to ensure that adequate nitric oxide levels are produced by endothelial tissues.

Abstract: A fast and accurate reverse-phase high pressure liquid chromatography (“RP-HPLC”) method for detecting amino acids in small volumes (e.g. less than 50 µL) of a biological sample, such as plasma. An assay for the simultaneous determination of ammonium and primary amino acids using RP-HPLC in samples such as plasma. A method for calculating intercellular volumes from a cell lysate to which a known volume and concentration of a non-naturally occurring amino acid is added.

Abstract: This invention provides methods for treating endothelial dysfunction by administering an effective amount of citrulline to a patient. The patients may be suffering from acute respiratory distress syndrome (ARDS), sepsis, or infection by COVID-19 (Coronavirus Disease 2019); COVID-19 patients may be at risk of developing endothelial dysfunction, or they may be experiencing endothelial dysfunction. The effective amount of citrulline is sufficient to reduce the uncoupling of endothelial nitric oxide synthase (eNOS) or to reduce the formation of free radicals. Citrulline may be administered orally; intravenously; or both orally and intravenously in a sequential manner. Sequential administration of citrulline may be in three phases, such as (a) an initial phase in which citrulline is administered orally, (b) an intermediate phase wherein citrulline is administered intravenously, and (c) a final phase wherein citrulline is administered orally.

Abstract: A computing platform is provided to perform continuous monitoring of new genomic variants from external genomic databases and compare the new variants to genomic sequencing results for patients stored in long term cloud storage. The platform provides alerts to clinicians if a patient's genomic sequencing results match one or more of the new genomic variants.

Abstract: The present invention provides compositions and methods of treating hyperphenylalaninemia (e.g., phenylketonuria) in a subject in need thereof comprising administering to the subject an effective amount of a phenylalanine dehydrogenase (PheDH) polypeptide. The present invention also provides pharmaceutical formulations comprising PheDH for lowering the phenylalanine concentration in the subject (e.g., in the intestines and/or blood).

Abstract: The present invention provides compositions and methods of treating hyperphenylalaninemia (e.g., phenylketonuria) in a subject in need thereof comprising administering to the subject an effective amount of a phenylalanine dehydrogenase (PheDH) polypeptide. The present invention also provides pharmaceutical formulations comprising PheDH for lowering the phenylalanine concentration in the subject (e.g., in the intestines and/or blood).

Abstract: An image analysis device includes circuitry that receives one or more input images and detects a plurality of anatomical landmarks on the one or more input images using a pre-determined face model. The circuitry extracts a plurality of geometric and local texture features based on the plurality of anatomical landmarks. The circuitry selects one or more condition-specific features from the plurality of geometric and local texture features. The circuitry classifies the one or more input images into one or more conditions based on the one or more condition-specific features.

Abstract: The present invention provides compositions and methods of treating hyperphenylalaninemia (e.g., phenylketonuria) in a subject in need thereof comprising administering to the subject an effective amount of a phenylalanine dehydrogenase (PheDH) polypeptide. The present invention also provides pharmaceutical formulations comprising PheDH for lowering the phenylalanine concentration in the subject (e.g., in the intestines and/or blood).

Abstract: An image analysis device includes circuitry that receives one or more input images and detects a plurality of anatomical landmarks on the one or more input images using a pre-determined face model. The circuitry extracts a plurality of geometric and local texture features based on the plurality of anatomical landmarks. The circuitry selects one or more condition-specific features from the plurality of geometric and local texture features. The circuitry classifies the one or more input images into one or more conditions based on the one or more condition-specific features.

Abstract: An image analysis device includes circuitry that receives one or more input images and detects a plurality of anatomical landmarks on the one or more input images using a pre-determined face model. The circuitry extracts a plurality of geometric and local texture features based on the plurality of anatomical landmarks. The circuitry selects one or more condition-specific features from the plurality of geometric and local texture features. The circuitry classifies the one or more input images into one or more conditions based on the one or more condition-specific features.

Abstract: An image analysis device includes circuitry that receives one or more input images and detects a plurality of anatomical landmarks on the one or more input images using a pre-determined face model. The circuitry extracts a plurality of geometric and local texture features based on the plurality of anatomical landmarks. The circuitry selects one or more condition-specific features from the plurality of geometric and local texture features. The circuitry classifies the one or more input images into one or more conditions based on the one or more condition-specific features.

Abstract: The present invention concerns the ?-glutamylcysteine treatment to reduce oxidative damage caused by ischemia/reperfusion events such as pulmonary hypertension, transplant, cardiac bypass and other surgeries, and trauma. In specific embodiments, preservation methods and apparatuses for preserving tissue for transplantation purposes is provided.